T11329 |
FT895
|
2225728-57-2
|
99.81%
|
|
FT895 is a selective and potent HDAC11 inhibitor with antifungal and antitumor activity that inhibits HDAC11 expression and limits EV71 replication in vitro.
|
T77732 |
HFY-4A
|
2094810-82-7
|
99.22%
|
|
HFY-4A is a novel HDAC inhibitor.HFY-4A has antitumour activity and has shown antiproliferative activity in breast cancer cells.
|
T77937 |
JPS014 TFA
|
|
98%
|
|
JPS014 TFA, a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimera (PROTAC), effectively degrades class I histone deacetylase (HDAC), ...
|
T77938 |
JPS016 TFA
|
|
98%
|
|
JPS016, a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimera (PROTAC), effectively degrades class I histone deacetylase (HDAC), part...
|
T78709 |
NT160
|
1418293-40-9
|
98%
|
|
NT160, a potent class-IIa HDAC inhibitor, exhibits an IC50 of 0.046 μM and has potential applications in central nervous system disease research [1].
|
T78766 |
HDAC-IN-59
|
2944459-43-0
|
98%
|
|
HDAC-IN-59 (compound 13a), a potent histone deacetylase (HDAC) inhibitor, enhances intracellular reactive oxygen species (ROS) production, induces DNA damage, ar...
|
T78767 |
HDAC-IN-60
|
2944459-58-7
|
98%
|
|
HDAC-IN-60 (compound 21a), a potent histone deacetylase (HDAC) inhibitor, promotes intracellular reactive oxygen species (ROS) production, induces DNA damage, ar...
|
T78768 |
HDAC6-IN-16
|
|
98%
|
|
HDAC6-IN-16 (compound 5c), a quinazolin-4(3H)-one-based inhibitor of histone deacetylase 6 (HDAC6), demonstrates an anticancer effect by inhibiting colony format...
|
T78769 |
HDAC6-IN-17
|
|
98%
|
|
HDAC6-IN-17 (compound 5b) is a potent inhibitor of HDAC6, exhibiting IC50 values of 150 nM for HDAC6, 1400 nM for HDAC8, and 2300 nM for HDAC4. It demonstrates c...
|
T78799 |
BChE/HDAC6-IN-1
|
2925457-27-6
|
98%
|
|
BChE/HDAC6-IN-1 is a dual BChE/HDAC6 inhibitor that exhibits potent and selective inhibition with IC50 values of 4 nM for BChE and 8.9 nM for HDAC6. It demonstra...
|
T78839 |
HDAC6-IN-19
|
|
98%
|
|
HDAC6-IN-19 (Compound 14g), an HDAC6 inhibitor with an IC50 of 2.68 nM, additionally inhibits HDAC1, HDAC2, and HDAC3, with IC50 values of 61.6 nM, 98.7 nM, and ...
|
T78861 |
HDAC8-IN-5
|
|
98%
|
|
HDAC8-IN-5 (Compound 6a), with an inhibitory concentration (IC50) of 28 nM, is a potent HDAC8 inhibitor suitable for cancer research [1].
|
T78906 |
CDK/HDAC-IN-3
|
2944087-54-9
|
98%
|
|
CDK/HDAC-IN-3 is an orally active dual inhibitor of HDACs and CDKs, offering potent and selective inhibition of CDK9, CDK12, CDK13, HDAC1, HDAC2, and HDAC3, with...
|
T78920 |
HDAC-IN-58
|
2071224-39-8
|
98%
|
|
HDAC-IN-58, a selective HDAC6 inhibitor, exhibits potent inhibitory activity with an IC50 of 2.06 nM, rendering it suitable for research into chronic neurodegene...
|
T78969 |
PB131
|
2924425-63-6
|
98%
|
|
PB131, a selective and brain-permeable HDAC6 inhibitor, exhibits high binding affinity (IC50: 1.8 nM) and potent anti-inflammatory activity, making it suitable f...
|
T79003 |
HDAC ligand-1
|
34840-28-3
|
98%
|
|
HDAC ligand-1 is a synthetic precursor utilized in the production of PROTAC-based HDAC degraders [1].
|
T79082 |
HDAC8-IN-4
|
1600528-05-9
|
98%
|
|
HDAC8-IN-4 is a selective HDAC8 inhibitor, exhibiting inhibitory activity with IC50 values of 0.15 μM for HDAC8 and 12 μM for HDAC3 [1].
|
T79366 |
SP-2-225
|
2364448-93-9
|
98%
|
|
SP-2-225, a selective inhibitor of HDAC6, augments the production of cancer-associated antigens and enhances macrophage antigen cross-presentation to T cells, de...
|
T79523 |
HDAC6-IN-18
|
|
98%
|
|
HDAC6-IN-18 (Compound 4), an irreversible and selective HDAC6 isoform inhibitor, exhibits potent anti-multiple myeloma effects. It demonstrates HDAC6 inhibitory ...
|
T79541 |
HDAC-IN-61
|
|
98%
|
|
HDAC-IN-61 (compound 12k) is a potent, orally active inhibitor of histone deacetylase (HDAC) with anticancer activity, exhibiting an IC50 of 30 nM against Bel-74...
|